Recent Updates
Recently added Catalysts
ALT

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

Monday, January 31, 2022 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Price reaction · baseline $7.2 (2022-01-28 close) · clean, no other ALT news in the window
day 0 close · peak
+12.1%
day 1
+10.8%
day 3
+3.7%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight

Full Press Release Details

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity.
ShareAdd on Google
Tags: ALT Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 31, 2022

Biotech snapshot

Cash runway
$519M liquidity · $8M/mo burn
~64 mo
Minimal dilution risk
Lead asset
ALT-801Phase 2
Obesity/Overweight →

Catalyst track record

+22%
best trade around ALT's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALT.

See every catalyst's timing & PoA →